source
- Seaport and Hemab price IPOs as Avalyn soars on Nasdaq debutThree biotechnology companies announced the pricing of their initial public offerings between Thursday and Friday, collectively targeting more than $850 million in proceeds. Seaport Therapeutics a…
- Psychedelic boom risks sidelining people of color despite new federal push and AbbVie's billion-dollar dealThe piece highlights that psychedelics are being praised for their therapeutic potential but still face scientific uncertainty and political debate. President Trump signed an executive order aimed…